Comparison of p16INK4a Immunocytochemistry with the HPV Polymerase Chain Reaction in Predicting High Grade Cervical Squamous Intraepithelial Lesions

  • Indarti, Junita (Department of Obstetrics and Gynecology, Ciptomangunkusumo National Referral Hospital) ;
  • Fernando, Darrell (Department of Obstetrics and Gynecology, Ciptomangunkusumo National Referral Hospital)
  • Published : 2013.09.30


Aim: To compare p16INK4a immunocytochemistry with the HPV polymerase chain reaction in predicting high grade cervical squamous intraepithelial lesions. Materials and Methods: This diagnostic case-control study was conducted from January 2010 until December 2010. We obtained 30 samples, classified according to the degree of cervical intraepithelial neoplasia (CIN): 11 samples for CIN 1, 9 samples for CIN 2, and 10 samples for CIN 3. HPV PCR, p16INK4a immunocytochemistry, and histopathological examination were performed on all samples. Statistical analysis was conducted using SPSS 20.0. Results: In predicting CIN 2-3, we found p16INK4a to have similar specificity and positive predictive value as HPV PCR (95%, 97.2% vs 96.7%), but better sensitivity (87.5% vs 72.5%) and negative predictive value (82.1% vs 67.6%). The most prevalent types of high-risk HPV in our study were HPV 33, 35, 58, 52, and 16. Conclusions: p16INK4a has better diagnostic values than HPV PCR and may be incorporated in the triage of ASCUS and LSIL to replace HPV PCR. Genotype distribution of HPV differs in each region, providing a challenge to develop HPV vaccines based on the epidemiology of HPV in that particular region.


Human papillomavirus;genotyping;polymerase chain reaction;p16INK4a;precancerous cervical lesions


  1. Suwiyoga IK (2006). Tes human papillomavirus sebagai skrining alternatif kanker leher rahim. Cermin Dunia Kedokteran, 151, 29-33.
  2. Schmeink C, Massuger L, Lenselink C, et al (2012). Prospective follow-up of 2065 young unscreened women to study human papillomavirus incidence and clearance. Int J Cancer, 133, 172-81.
  3. Shen Y, Gong JM, Li YQ, et al (2013). Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province, China. Clin Chim Acta, 415, 297-301.
  4. Vet JN, de Boer MA, van den Akker BE, et al (2008). Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. Br J Cancer, 99, 214-8.
  5. von Knebel Doeberitz M (2002). New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer, 38, 2229-42.
  6. Wenham RM, Lancaster JM, Berchuck A (2002). Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol, 16, 483-97.
  7. World Health Organization (2006). Comprehensive cervical cancer control: a guide to essential practice. World Health Organization, Geneva, p 16-7, 92-100.
  8. Bonanni P, Boccalini S, Bechini A (2009). Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine, 27, 46-53.
  9. Hacker NF (2005). Cervical cancer. In 'Practical gynecologic oncology', eds Berek JS. Lippincott Williams & Wilkins, Philadelphia p 337-95.
  10. de Villiers EM, Fauquet C, Broker TR, et al (2004). Classification of papillomaviruses. Virology, 324, 17-27.
  11. Ekalaksananan T, Pientong C, Kongyingyoes B, et al (2011). Combined p16INK4a and human papillomavirus testing improves the prediction of cervical intraepithelial neoplasia (CIN II-III) in Thai patients with low-grade cytological abnormalities. Asian Pac J Cancer Prev, 12, 1777-83.
  12. Eleuterio J Jr, Giraldo PC, Goncalves AK, et al (2007). Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4a and high-risk human papillomavirus. Acta Obstet Gynecol Scand, 86, 94-8.
  13. Kim J, Kim BK, Lee CH, et al (2012). Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. Int J Gynecol Cancer, 22, 1570-6.
  14. Lenselink CH, Melchers WJ, Quint WG, et al (2008). Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One, 3, 3743.
  15. Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
  16. Nasioutziki M, Daniilidis A, Dinas K, et al (2011). The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer, 21, 79-85.
  17. Roelens J, Reuschenbach M, von Knebel Doeberitz M, et al (2012). p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and metaanalysis. Cancer Cytopathol, 120, 294-307.
  18. Rositch AF, Koshiol J, Hudgens MG, et al (2012). Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer, 133, 1271-85.